Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A site-wide NIH banner was added with transition updates and a statement about replacing “Artificial Intelligence” with “Super Intelligence.” The site revision advanced from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:33:26.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T22:35:15.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error (with minimal 403 page content) instead of rendering the study record, indicating restricted access or a loading/navigation problem.
    Difference
    19%
    Check dated 2026-09-22T22:45:24.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The page now displays a new revision tag, Revision: v3.7.0, replacing the prior v3.6.6. This indicates the document or component has been updated to a newer version.
    Difference
    0.1%
    Check dated 2026-09-15T21:35:12.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page’s revision tag was updated from v3.6.5 to v3.6.6, reflecting a platform-level update; the study details themselves remain unchanged.
    Difference
    0.1%
    Check dated 2026-09-01T18:17:46.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The study's list of identifiers now includes a line for '2014 ( U.S. NIH Grant/Contract )', indicating NIH funding for the trial.
    Difference
    0.1%
    Check dated 2026-08-25T20:48:33.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.